ATAD2 also negatively regulates the expression of APC that inhibits β-catenin and accelerates the occurrence of HCC, and ATAD2 promotes HCC progression by inhibiting the p53/p38-mediated apoptosis signaling pathway (Figure 2) [25,26,27,28,29]. This evidence concerns the gene APC and hepatocellular carcinoma.